In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B

PLoS ONE

Volumn 10, Issue 2, 2015, Pages

  Silva, Izabella T ^a,b   Carvalho, Annelise ^a   Lang, Karen L ^a   Dudek, Sabine E ^b   Masemann, Dörthe ^b   Durán, Fernando J ^c   Caro, Miguel S B ^a   Rapp, Ulf R ^d   Wixler, Viktor ^b   Schenkel, Eloir P ^a   Simões, Cláudia M O ^a   Ludwig, Stephan ^b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 DEOXY 2 AMINE CUCURBITACIN E; CASPASE 3; CUCURBITACIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RAF PROTEIN; STAT3 PROTEIN; STAUROSPORINE; SURFACTANT PROTEIN C; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; APOPTOSIS REGULATORY PROTEIN; CUCURBITACIN B; PHOSPHATIDYLINOSITOL 3 KINASE; TRITERPENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CONTROLLED STUDY; DRUG STRUCTURE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ALVEOLUS EPITHELIUM; MALE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINT; CYTOSKELETON; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; GENETICS; LUNG NEOPLASMS; METABOLISM; MOUSE; PATHOLOGY; PHOSPHORYLATION; SYNTHESIS; TRANSGENIC MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARCINOMA, NON-SMALL-CELL LUNG; CASPASE 3; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOSKELETON; DISEASE MODELS, ANIMAL; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RAF KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRITERPENES; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922896568     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0117794     Document Type: Article

References (68)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917. doi: 10.1002/ijc.25516 PMID: 21351269
2. Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18: 1059-1068. PMID: 11829087
3. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674. doi: 10.1016/j.cell.2011.02.013 PMID: 21376230
4. Henson ES, Gibson SB (2006) Surviving cell death through epidermal growth factor (EGF) signal transduction pathways: implications for cancer therapy. Cell Signal 18: 2089-2097. PMID: 16815674
5. Haura EB, Cress WD, Chellappan S, Zheng Z, Bepler G (2004) Antiapoptotic signaling pathways in non-small-cell lung cancer: biology and therapeutic strategies. Clin Lung Cancer 6: 113-122. PMID: 15476597
6. Lee HY, Srinivas H, Xia D, Lu Y, Superty R, et al. (2003) Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival. J Biol Chem 278: 23630-23638. PMID: 12714585
7. Altomare DA, Testa JR (2005) Perturbations of the AKT signaling pathway in human cancer. Oncogene 24: 7455-7464. PMID: 16288292
8. Duffy A, Kummar S (2009) Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors. Target Oncol 4: 267-273. doi: 10.1007/s11523-009-0125-x PMID: 19899001
9. Al Zaid Siddiquee K, Turkson J (2008) STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res 18: 254-267. doi: 10.1038/cr.2008.18 PMID: 18227858
10. Mehta RG, Murillo G, Naithani R, Peng X (2010) Cancer chemoprevention by natural products: how far have we come? Pharm Res 27: 950-961. doi: 10.1007/s11095-010-0085-y PMID: 20238150
11. Newman DJ, Cragg GM (2012) Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 75: 311-335. doi: 10.1021/np200906s PMID: 22316239
12. Lee KW, Bode AM, Dong Z (2011) Molecular targets of phytochemicals for cancer prevention. Nat Rev Cancer 11: 211-218. doi: 10.1038/nrc3017 PMID: 21326325
13. Cragg GM, Newman DJ (2013) Natural products: A continuing source of novel drug leads. Biochim Biophys Acta 1830: 3670-3695. doi: 10.1016/j.bbagen.2013.02.008 PMID: 23428572
14. Chen JC, Chiu MH, Nie RL, Cordell GA, Qiu SX (2005) Cucurbitacins and cucurbitane glycosides: Structures and biological activities. Nat Prod Rep 22: 386-399. PMID: 16010347
15. Rios JL, Andujar I, Escandell JM, Giner RM, Recio MC (2012) Cucurbitacins as inducers of cell death and a rich source of potential anticancer compounds. Curr Pharm Des 18: 1663-1676. PMID: 22443631
16. Alghasham AA (2013) Cucurbitacins - a promising target for cancer therapy. Int J Health Sci (Qassim) 7: 77-89. PMID: 23559908
17. Chen X, Bao J, Guo J, Ding Q, Lu J, et al. (2012) Biological activities and potential molecular targets of cucurbitacins: a focus on cancer. Anticancer Drugs 23: 777-787. doi: 10.1097/CAD.0b013e3283541384 PMID: 22561419
18. Bernard SA, Olayinka OA (2010) Search for a novel antioxidant, antiinflammatory/analgesic or anti-proliferative drug: Cucurbitacins hold the ace. J Med Plant Res 4: 2821-2826.
19. Duangmano S, Sae-Lim P, Suksamrarn A, Domann FE, Patmasiriwat P (2012) Cucurbitacin B inhibits human breast cancer cell proliferation through disruption of microtubule polymerization and nucleophosmin/B23 translocation. BMC Complement Altern Med 12: 185. doi: 10.1186/1472-6882-12-185 PMID: 23062075
20. Kausar H, Munagala R, Bansal SS, Aqil F, Vadhanam MV, et al. (2013) Cucurbitacin B potently suppresses non-small-cell lung cancer growth: Identification of intracellular thiols as critical targets. Cancer Lett 332: 35-45. doi: 10.1016/j.canlet.2013.01.008 PMID: 23340170
21. Lang KL, da Rosa Guimarães T, Rocha Machado V, Zimmermann LA, Silva IT, et al. (2011) New Cytotoxic Cucurbitacins from Wilbrandia ebracteata Cogn. Planta Med 77: 1648-1651. doi: 10.1055/s-0030-1270962 PMID: 21472651
22. Lang KL, Silva IT, Zimmermann LA, Machado VR, Teixeira MR, et al. (2012) Synthesis and cytotoxic activity evaluation of dihydrocucurbitacin B and cucurbitacin B derivatives. Bioorg Med Chem 20: 3016-3030. doi: 10.1016/j.bmc.2012.03.001 PMID: 22472043
23. Duncan KL, Duncan MD, Alley MC, Sausville EA (1996) Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol 52: 1553-1560. PMID: 8937470
24. Ren S, Ouyang DY, Saltis M, Xu LH, Zha QB, et al. (2012) Anti-proliferative effect of 23,24-dihydrocucurbitacin F on human prostate cancer cells through induction of actin aggregation and cofilin-actin rod formation. Cancer Chemother Pharmacol 70: 415-424. doi: 10.1007/s00280-012-1921-z PMID: 22814677
25. Yasuda S, Yogosawa S, Izutani Y, Nakamura Y, Watanabe H, et al. (2010) Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells. Mol Nutr Food Res 54: 559-565. doi: 10.1002/mnfr.200900165 PMID: 19937855
26. Abdelwahab SI, Hassan LE, Abdul Majid AM, Yagi SM, Mohan S, et al. (2012) Cucurbitacin L 2-O-beta-Glucoside Demonstrates Apoptogenesis in Colon Adenocarcinoma Cells (HT-29): Involvement of Reactive Oxygen and Nitrogen Species Regulation. Evid Based Complement Alternat Med 2012: 490136. doi: 10.1155/2012/490136 PMID: 22685485
27. Silva IT, Teixeira MR, Lang KL, Guimaraes TR, Dudek SE, et al. (2013) Proliferative inhibition and apoptotic mechanism on human non-small-cell lung Cancer (A549 Cells) of a novel cucurbitacin from Wilbrandia ebracteata Cogn. Int J Cancer Res 9: 54-68.
28. Kerkhoff E, Fedorov LM, Siefken R, Walter AO, Papadopoulos T, et al. (2000) Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein. Cell Growth Differ 11: 185-190. PMID: 10775035
29. Kolch W, Heidecker G, Lloyd P, Rapp UR (1991) Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349: 426-428. PMID: 1992343
30. von Gise A, Lorenz P, Wellbrock C, Hemmings B, Berberich-Siebelt F, et al. (2001) Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 21: 2324-2336. PMID: 11259582
31. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63. PMID: 6606682
32. Filippi-Chiela EC, Thome MP, Bueno e Silva MM, Pelegrini AL, Ledur PF, et al. (2013) Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells. BMC Cancer 13: 147. doi: 10.1186/1471-2407-13-147 PMID: 23522185
33. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. PMID: 11846609
34. Bellomo G, Mirabelli F (1992) Oxidative stress and cytoskeletal alterations. Ann N Y Acad Sci 663: 97-109. PMID: 1482106
35. Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770-776. PMID: 11048727
36. Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8: 547-566. doi: 10.1038/nrd2907 PMID: 19568282
37. Johnson AL, Langer JS, Bridgham JT (2002) Survivin as a cell cycle-related and antiapoptotic protein in granulosa cells. Endocrinology 143: 3405-3413. PMID: 12193553
38. Heidecker G, Huleihel M, Cleveland JL, Kolch W, Beck TW, et al. (1990) Mutational activation of c-raf-1 and definition of the minimal transforming sequence. Mol Cell Biol 10: 2503-2512. PMID: 2188091
39. Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, et al. (1983) Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci U S A 80: 4218-4222. PMID: 6308607
40. Lang KL, Silva IT, Machado VR, Zimmermann LA, Caro MS, et al. (2014) Multivariate SAR and QSAR of cucurbitacin derivatives as cytotoxic compounds in a human lung adenocarcinoma cell line. J Mol Graph Model 48: 70-79. doi: 10.1016/j.jmgm.2013.12.004 PMID: 24378396
41. Zhu JS, Ouyang DY, Shi ZJ, Xu LH, Zhang YT, et al. (2012) Cucurbitacin B induces cell cycle arrest, apoptosis and autophagy associated with G actin reduction and persistent activation of cofilin in Jurkat cells. Pharmacology 89: 348-346. doi: 10.1159/000338757 PMID: 22699368
42. Tannin-Spitz T, Grossman S, Dovrat S, Gottlieb HE, Bergman M (2007) Growth inhibitory activity of cucurbitacin glucosides isolated from Citrullus colocynthis on human breast cancer cells. Biochem Pharmacol 73: 56-67. PMID: 17049494
43. Fletcher S, Drewry JA, Shahani VM, Page BDG, Gunning PT (2009) Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem Cell Biol 87: 825-833. doi: 10.1139/o09-044 PMID: 19935868
44. Sun J, Blaskovich MA, Jove R, Livingston SK, Coppola D, et al. (2005) Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity. Oncogene 24: 3236-3245. PMID: 15735720
45. Wiart C (2013) The Definition and Significance of Cucurbitacin B a STAT3 Inhibitors. Cancer Lett 328: 188. doi: 10.1016/j.canlet.2012.01.033 PMID: 22306703
46. Besson A, Dowdy SF, Roberts JM (2008) CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159-169. doi: 10.1016/j.devcel.2008.01.013 PMID: 18267085
47. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR (2000) The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci 113: 4363-4371. PMID: 11069780
48. Li F, Ackermann EJ, Bennett CF, Rothermel AL, Plescia J, et al. (1999) Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nat Cell Biol 1: 461-466. PMID: 10587640
49. Mobahat M, Narendran A, Riabowol K (2014) Survivin as a preferential target for cancer therapy. Int J Mol Sci 15: 2494-2516. doi: 10.3390/ijms15022494 PMID: 24531137
50. Shin S, Sung BJ, Cho YS, Kim HJ, Ha NC, et al. (2001) An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry 40: 1117-1123. PMID: 11170436
51. Reed JC (2001) The Survivin saga goes in vivo. J Clin Invest 108: 965-969. PMID: 11581297
52. Dubrez-Daloz L, Dupoux A, Cartier J (2008) IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 7: 1036-1046. PMID: 18414036
53. Jing N, Tweardy DJ (2005) Targeting Stat3 in cancer therapy. Anticancer Drugs 16: 601-607. PMID: 15930886
54. Blaskovich MA, Sun J, Cantor A, Turkson J, Jove R, et al. (2003) Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 63: 1270-1279. PMID: 12649187
55. Chan KT, Li K, Liu SL, Chu KH, Toh M, et al. (2010) Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562. Cancer Lett 289: 46-52. doi: 10.1016/j.canlet.2009.07.015 PMID: 19700240
56. Chan KT, Meng FY, Li Q, Ho CY, Lam TS, et al. (2010) Cucurbitacin B induces apoptosis and S phase cell cycle arrest in BEL-7402 human hepatocellular carcinoma cells and is effective via oral administration. Cancer Lett 294: 118-124. doi: 10.1016/j.canlet.2010.01.029 PMID: 20153103
57. Lee DH, Thoennissen NH, Goff C, Iwanski GB, Forscher C, et al. (2011) Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma. Cancer Lett 306: 161-170. doi: 10.1016/j.canlet.2011.03.001 PMID: 21440986
58. Guo J, Wu G, Bao J, Hao W, Lu J, et al. (2014) Cucurbitacin B induced ATM-mediated DNA damage causes G2/M cell cycle arrest in a ROS-dependent manner. PLoS One 9: e88140. doi: 10.1371/journal.pone.0088140 PMID: 24505404
59. Guo J, Zhao W, Hao W, Ren G, Lu J, et al. (2014) Cucurbitacin B Induces DNA Damage, G2/M Phase Arrest, and Apoptosis Mediated by Reactive Oxygen Species (ROS) in Leukemia K562 Cells. Anticancer Agents Med Chem 14: 1146-1153. PMID: 24893803
60. Gupta P, Srivastava SK (2014) Inhibition of Integrin-HER2 signaling by Cucurbitacin B leads to in vitro and in vivo breast tumor growth suppression. Oncotarget 5: 1812-1828. PMID: 24729020
61. Coffey MC, Strong JE, Forsyth PA, Lee PW (1998) Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334. PMID: 9812900
62. Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, et al. (2004) ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. British journal of cancer 90: 1047-1052. PMID: 14997206
63. Ciuffreda L, McCubrey JA, Milella M (2009) Signaling Intermediates (PI3K/PTEN/AKT/mTOR and RAF/MEK/ERK Pathways) as Therapeutic Targets for Anti-Cancer and Anti-Angiogenesis Treatments. Curr Signal Transduct Ther 4: 130-143.
64. Herrera R, Sebolt-Leopold JS (2002) Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention. Trends Mol Med 8: S27-31. PMID: 11927284
65. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, et al. (2004) PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204. PMID: 15023437
66. Blasco RB, Francoz S, Santamaria D, Canamero M, Dubus P, et al. (2011) c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell 19: 652-663. doi: 10.1016/j.ccr.2011.04.002 PMID: 21514245
67. Cooper WA, Lam DC, O'Toole SA, Minna JD (2013) Molecular biology of lung cancer. J Thorac Dis 5 Suppl 5: S479-490. doi: 10.3978/j.issn.2072-1439.2013.08.03 PMID: 24163741
68. Vicent S, Lopez-Picazo JM, Toledo G, Lozano MD, Torre W, et al. (2004) ERK1/2 is activated in non-small-cell lung cancer and associated with advanced tumours. Br J Cancer 90: 1047-1052. PMID: 14997206